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Abstract
Background: Invasive	candidiasis	 (IC)	 is	a	common	cause	of	mortality	 in	solid	organ	
transplant	 recipients	 (OTRs),	 but	 knowledge	 of	 epidemiology	 in	 this	 population	 is	
limited.
Method: The	present	analysis	describes	data	from	15	US	centers	that	prospectively	
identified	IC	from	nearly	17	000	OTRs.	Analyses	were	undertaken	to	determine	pre-
dictors	of	infection	and	mortality.
Results: A	total	of	639	cases	of	 IC	were	 identified.	The	most	common	species	was	
Candida albicans	(46.3%),	followed	by	Candida glabrata	(24.4%)	and	Candida parapsilo-
sis	(8.1%).	In	68	cases	>1	species	was	identified.	The	most	common	infection	site	was	
bloodstream	(44%),	followed	by	intra-	abdominal	(14%).	The	most	frequently	affected	
allograft	groups	were	liver	(41.1%)	and	kidney	(35.3%).	All-	cause	mortality	at	90	days	
was	26.5%	for	all	species	and	was	highest	for	Candida tropicalis	(44%)	and	C. parapsilo-
sis	(35.2%).	Non-	white	race	and	female	gender	were	more	commonly	associated	with	
non- albicans	species.	A	high	rate	of	breakthrough	 IC	was	seen	 in	patients	receiving	
antifungal	prophylaxis	(39%).	Factors	associated	with	mortality	include	organ	dysfunc-
tion,	 lung	 transplant,	 and	 treatment	with	a	polyene	antifungal.	The	only	modifiable	
factor	 identified	was	 choice	 of	 antifungal	 drug	 class	 based	 upon	 infecting	Candida 
species.
Conclusion: These	data	highlight	the	common	and	distinct	features	of	IC	in	OTRs.
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1  | INTRODUCTION
Advances	 in	 transplantation	 biology,	 organ	 procurement,	 surgical	
techniques,	and	immunosuppressive	therapy	have	made	organ	trans-
plantation	an	effective	option	 for	 the	management	of	organ	 failure,	
with	a	1-	year	survival	>60%-	80%.	However,	infection	remains	one	of	
the	most	challenging	complications	of	solid	organ	transplantation.1–5 
The	most	prevalent	mycosis	is	invasive	candidiasis	(IC)	and	is	associ-
ated	with	considerable	mortality.6–13	An	understanding	of	the	epide-
miology	and	organ	transplant	type-	specific	risk	factors	and	outcomes	
may	identify	effective	prevention	and	treatment	strategies.
The	 Transplant-Associated	 Infection	 Surveillance	 Network	
(TRANSNET)	was	 established	 in	 2001	 as	 a	 prospective	 surveillance	
group	for	the	purpose	of	understanding	the	burden	of	invasive	fungal	
infections,	and	to	better	define	patients	at	risk	and	outcome	of	these	
infections.14,15	 The	 group	 included	 15	 geographically	 diverse	 trans-
plant	centers	in	the	United	States	that	provided	infection	surveillance	
data	for	invasive	fungal	infections	in	solid	organ	transplant	recipients	
(OTRs).	The	emphasis	of	 this	 report	 is	 to	examine	 the	epidemiology	
and	outcomes	of	IC.
2  | METHODS
2.1 | Study population
Fifteen	 TRANSNET	 sites	 performed	 transplantation	 and	 provided	
prospective	surveillance	on	these	patients.	The	period	of	IC	infection	
surveillance	was	2001	through	2006,	and	included	all	OTRs	who	de-
veloped	an	 IC	 infection	during	this	period.	 Information	collected	on	
patients	included	demographics	(age,	gender,	race/ethnicity)	and	type	
of	transplant.	Follow-	up	information	for	the	cohort	was	gathered	to	
obtain	date	of	last	follow-	up	and	patient	status	(alive	or	dead).
2.2 | Definitions and case identification
Only	proven	and	probable	IC	infections	as	defined	by	the	EORTC/MSG	
criteria16,17	 were	 included	 (see	 definitions	 in	 supplemental	 Data	 S1).	
Lower	 urinary	 tract	 infection	 and	 mucosal	 infections	 were	 excluded.	
Cases	 were	 reviewed	 to	 determine	 individual	 case	 validity	 by	 a	 Data	
Review	Committee.	 IC	was	 identified	 prospectively	 among	 this	 popu-
lation	by	establishing	monthly	patient	 logs	of	 transplant	 recipients,	 re-
viewing	pertinent	culture	data	and	histopathology,	as	well	as	through	the	
routine	contact	with	transplant	physicians	and	coordinators.	Case	infor-
mation	 included	 infection	site,	 culture	data,	method	of	diagnosis,	date	
and	type	of	transplant,	history	of	rejection,	comorbid	conditions,	cyto-
megalovirus	infection	(based	on	tissue	histopathology	or	viremia),	recent	
immunosuppressive	and	antifungal	treatment	data,	and	patient	status	at	
least	3		months	after	initial	diagnosis	of	IC	infection.
2.3 | Microbiologic methods
Available	cultures	and	histopathological	specimens	were	processed	at	
the	participating	hospitals.	Species	identification	was	performed	using	
routine	methods	at	the	participants’	affiliated	 laboratories.	Available	
fungal	 isolates	were	 forwarded	 to	 the	 Centers	 for	Disease	 Control	
Mycotic	Diseases	Branch	for	confirmation	of	identification.
2.4 | Data analysis
Univariate	analyses	to	assess	the	relationship	between	variables	and	
survival	 were	 performed	 by	 tabulating	 these	 measures	 in	 the	 sur-
vivor	and	non-	survivor	cohorts.	The	χ2	 test	or	 the	Fisher	exact	 test	
was	 used	 to	 assess	 statistical	 significance	 for	 categorical	 variables	
and	the	Wilcoxon	rank-	sum	test	was	used	for	continuous	variables.	
Multivariable	analyses	of	factors	associated	with	mortality	were	per-
formed	 using	 stepwise	 multiple	 logistic	 regression	 via	 generalized	
estimating	equations.	We	chose	to	model	 the	correlation	of	 the	re-
peated	measures	on	some	of	the	individuals	with	a	compound	sym-
metry	covariance	structure.	The	criterion	for	entry	into	the	model	was	
significant	at	α=.20,	whereas	the	criterion	for	remaining	in	the	model	
was	 significant	 at	α=.05.	Odds	 ratios	 (ORs)	 and	corresponding	95%	
confidence	intervals	(CIs)	were	calculated.	A	multiple	logistic	regres-
sion	model	containing	the	best	predictor	variables	obtained	from	the	
stepwise	analysis	was	then	run	using	all	available	data	in	order	to	ob-
tain	more	robust	estimates	of	the	ORs,	95%	CIs,	and	P-values.	Once	
final	models	were	achieved	through	the	stepwise	process,	a	potential	
interaction	between	prednisone	use	and	rejection	was	evaluated	by	
incorporating	an	interaction	term	into	the	final	model.
A	 time-	to-	death	 analysis	 was	 also	 performed.	 First,	 a	 univariate	
analysis	 comparing	 transplant	 type,	 and	 another	 comparing	Candida 
species	were	conducted	via	Kaplan–Meier	estimation	and	the	log-	rank	
test.	To	validate	the	above	logistic	regression	results,	multivariate	anal-
yses	were	run	using	Cox	regression	incorporating	the	final	model	terms	
found	in	logistic	models.	All	statistical	tests	were	2-	tailed	and	were	per-
formed	using	a	5%	significance	level	(α=.05).	Statistical	analyses	were	
performed	using	the	R	statistical	computing	environment,	version	2.11.
3  | RESULTS
3.1 | Epidemiology of IC among OTRs
A	total	of	639	cases	of	 IC	 (533	proven	and	106	probable)	occurred	
in	594	OTRs	from	among	nearly	17	000	patients	under	surveillance	
in	the	study	period.	The	demographic	characteristics,	transplantation	
type,	 and	 survival	 in	OTRs	with	 IC	 overall,	 by	 transplant	 type,	 and	
Candida	species,	are	presented	in	Table	1.	The	rank	order	of	most	fre-
quently	encountered	species	was	Candida albicans	 (46.3%),	followed	
by Candida glabrata	 (24.4%),	 and	 Candida parapsilosis	 (8.1%).	 In	 68	
cases	>1	Candida	species	was	involved	in	IC.	The	most	common	site	
of	IC	was	bloodstream	in	44%	of	cases,	followed	by	intra-	abdominal	
infection	(14%).	Among	the	635	OTRs	with	IC,	infection	was	observed	
most	commonly	in	liver	(261,	41.1%),	followed	by	kidney	(224,	35.3%),	
kidney-	pancreas	 (58,	9.1%),	and	 lung	(55,	8.7%)	 (4	cases	were	miss-
ing	organ	 type	 classification).	 The	median	time	 to	onset	 for	 IC	was	
80	days	post	transplantation	(interquartile	range	[IQR]	14-	545	days).	
In	total,	205	infections	were	diagnosed	early	post	transplant	(within	
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30	days)	 and	 411	were	 diagnosed	 late.	 The	mean	 patient	 age	 was	
47.4	years	 and	 the	 majority	 of	 patients	 were	 Caucasian	 (82.2%).	
Several	 comorbidities	were	 common	 in	 cases,	 including	 renal	 (287,	
44.9%)	and	hepatic	 (150,	23.5%)	 insufficiency,	malnutrition	 (29.3%),	
and	diabetes	(299,	46.8%).	In	addition,	allograft	rejection	was	present	
in	38%	(242)	of	cases.	Patients	often	received	antifungal	prophylaxis	
(nearly	40%)	at	the	time	of	the	diagnosis	of	 IC,	most	with	a	triazole	
(fluconazole	most	frequent;	triazole	29.9%,	amphotericin	B	[AmB]	for-
mulation	6.1%,	echinocandin	3.9%).	For	treatment	of	IC,	almost	66%	
of	 patients	 received	 a	 triazole,	 compared	with	 an	AmB	 formulation	
(28%)	or	an	echinocandin	(36%).
3.2 | Characteristics of IC among Candida species
Survival	by	Candida	species	varied	as	shown	in	Figure	1.	The	90-	day	
mortality	by	species	was	22.6%	for	C. albicans,	27.7%	for	C. glabrata,	
31.5%	 for	Candida krusei,	 35.2%	 for	C. parapsilosis,	 and	 highest	 for	
Candida tropicalis	 (44%).	 Epidemiological	 features	 in	 patients	 with	
C. albicans	 (n=296)	 were	 contrasted	 with	 those	 who	 had	 infection	
with	the	second	most	common	species,	C. glabrata	 (n=156).	Logistic	
regression	identified	both	female	gender	and	black	race	as	independ-
ent	demographic	predictors	of	invasive	C. glabrata	infection	(Table	2).	
Triazole	antifungal	use	prior	to	infection	was	linked	to	C. glabrata in-
fection.18–20	The	patient	age	associated	with	C. glabrata	in	this	cohort	
was	49	years.21–24	An	additional	 treatment	 variable	 associated	with	
C. glabrata	infection	was	use	of	methyprednisolone	(MPS).
We	also	compared	patients	with	C. albicans	(n=296)	to	those	with	
the	aggregate	non-	albicans	species	population	(n=258).	 Independent	
risk	factors	for	IC	caused	by	non-	albicans	species	were	similar	to	those	
for	C. glabrata	alone	and	included	black	race,	female	gender,	triazole	
antifungal	 prophylaxis,	 kidney	 transplant	 over	 other	 types	 of	 organ	
transplant,	and	MPS	use.	Distinct	risk	factors	associated	with	C. para-
psilosis	included	younger	age	(40.3	years,	IQR	28.0-	58.7).	In	addition,	
antifungal	prophylaxis	with	an	echinocandin	drug	was	more	common	
in	the	patients	with	C. parapsilosis	breakthrough	infections.	Among	the	
non- albicans	species,	late	disease	onset	(>90	days)	was	also	most	com-
mon	for	C. parapsilosis	infection.
3.3 | Characteristics of IC among 
transplant organ types
In	total,	48	heart,	55	lung,	38	pancreas,	224	kidney,	261	liver,	and	58	
kidney-	pancreas	OTRs	were	diagnosed	with	IC.	The	aggregate	mortal-
ity	associated	with	IC	was	26.5%,	but	was	greatest	in	the	heart,	lung,	
and	 liver	 transplant	 cohorts	 (heart	 25.5%,	 lung	 36.4%,	 liver	 30.9%,	
pancreas	13.2%,	kidney	22.3%,	kidney-	pancreas	15.5%).	Allograft	re-
jection	was	 common	 in	 the	 aggregate	 IC	 population,	 but	was	most	
common	in	heart	transplant	recipients	(52.1%	vs	[32.4%-	41.4%]).	Use	
of	MPS	was	also	more	common	in	the	heart	transplant	group	(33.3%	
vs	[13.8%-	18.2%]).
Bloodstream	infection	was	the	most	common	manifestation	across	
the	 transplant	 organ	 types.	 Intra-	abdominal	 infection	was	 the	 next	
most	frequent	infection	site	and	was	associated	with	allografts	below	
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Variable Odds ratio Lower Upper P- value
C. albicans	vs	non-	albicans Candida
Black 0.59 0.35 0.98 .040
Female 0.65 0.44 0.96 .032
Methyprednisolone 0.57 0.33 0.97 .039
Pulmonary	site 3.22 1.26 8.24 .015
CHF 2.14 0.92 5.00 .078
Kidney 0.59 0.39 0.90 .015
Pancreatitis	disease 2.44 1.02 5.81 .045
Triazole	therapy 0.37 0.24 0.57 <.001
C. albicans	vs	C. glabrata
Black 0.57 0.31 1.03 .063
Female 0.46 0.29 0.72 .001
Age 0.98 0.97 1.00 .028
Methyprednisolone 0.42 0.24 0.74 .003
Triazole	prophylaxis 0.39 0.24 0.62 <.001
Candida parapsilosis	vs	non-	parapsilosis Candida
Age 0.98 0.96 0.99 .011
Early	disease 0.43 0.19 0.95 .037
Echinocandin	therapy 4.06 1.47 11.18 .007
CHF,	congestive	heart	failure.
TABLE  2 Multivariate	analysis	of	risk	
factors	for	infection	with	select	Candida 
species
F IGURE  1 Kaplan–Meier	probability	
of	survival	in	solid	organ	transplant	(SOT)	
recipients	according	to	Candida	species
All SOT Combined
Albicans
Glabrata
Krusei
Parapsilosis
Tropicalis
Other
635 583 548 521 499 483 468
296 279 263 251 242 234 229
155 142 130 121 115 113 113
19 14 14 14 13 13 13
51 46 44 42 39 37 33
25 22 19 18 17 15 14
89 80 78 75 73 71 66
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the	diaphragm	 (pancreas	26.3%,	 liver	20.7%,	kidney-	pancreas	19%).	
Antifungal	prophylaxis	was	common	among	all	OTRs	with	 IC	 (39%);	
however,	 this	practice	was	most	common	for	 the	heart	and	 lung	al-
lograft	recipients	(heart	64.8%,	lung	70.9%	vs	pancreas	28.9%,	kidney	
29.9%,	liver	44.8%,	and	kidney-	pancreas	51.7%).	Among	patients	who	
developed	 IC,	 antifungal	 prophylaxis	with	 a	 triazole	was	most	 com-
monly	administered	to	kidney-	pancreas	transplant	(26/58	44.8%)	and	
lung	transplant	recipients	(24/55	43.6%).	AmB	and	echinocandin	pro-
phylaxis	were	much	less	common	in	all	OTRs.	Use	of	these	agents	was	
observed	predominantly	 in	 the	 liver	 transplant	cohort	 (amphotericin	
33/261	12.6%	and	echinocandin	14/261	5.4%).
Triazoles	were	the	most	common	antifungal	drugs	used	for	treat-
ment	 of	 IC.	 This	 treatment	 was	 particularly	 frequent	 in	 pancreas	
(28/38;	 73.7%)	 and	 kidney	 transplant	 recipients	 (158/224;	 70.5%).	
Additional	characteristics	in	the	different	transplant	types	are	shown	
in	Table	S1.
3.4 | Predictors of mortality in patients with IC
Ninety-	day	mortality	 for	all	patients	was	168/635	 (26.5%).	Kaplan–
Meier	estimate	of	30-	day	survival	was	85.5%.	Survival	was	 statisti-
cally	 different	 among	 Candida	 species	 (Figure	1).	 The	 mortality	 for	
non- albicans	 group	 was	 higher	 than	 for	 C. albicans	 (non-	albicans 
[80/255]	31.4%	vs	C. albicans	 [67/296]	22.6%,	P=.02).	Much	of	this	
difference	was	driven	by	C. glabrata.	However,	mortality	 associated	
with	C. parapsilosis	and	C. tropicalis	infection	was	also	high	(35.2%	and	
44%	respectively).	Independent	predictors	of	mortality	in	OTRs	with	
IC	 across	 all	Candida	 species	 included	 renal	 impairment,	 congestive	
heart	 failure,	 lung	 transplant,	 and	 treatment	with	 an	AmB	 formula-
tion	 (Table	3).	 Prednisone	use	 and	 IC	 in	 the	 early	 transplant	 period	
(30	days)	were	associated	with	reduced	risk	of	mortality.
We	performed	several	subgroup	analyses	to	explore	unique	out-
come	 factors	 based	 on	Candida	 species,	 organ	 transplant	 type,	 and	
infection	 site	 (Table	4).	 The	 majority	 of	 elements	 correlating	 with	
outcome	were	 similar	 among	 the	 organism,	 host,	 and	 disease	 state	
groups.	Organ	dysfunction,	 infection	dissemination,	and	allograft	re-
jection	were	shared	features	among	those	patients	who	died.	A	unique	
association	among	the	subgroups	included	the	relative	protection	for	
patients	receiving	echinocandins	in	the	setting	of	C. glabrata	infection	
(OR	0.45,	 95%	CI	 0.17-	0.97).	 Conversely,	 a	 trend	was	 seen	 toward	
reduced	efficacy	with	this	antifungal	drug	class	for	C. parapsilosis in-
fection	(61.1%	in	those	that	died	vs	30.3%	in	survivors,	P=.03).	Among	
the	renal	transplant	cohort,	the	use	of	AmB	was	 linked	to	poor	out-
come	(42%	in	those	who	died	vs	other	21.8%	in	survivors,	P<.001).
4  | DISCUSSION
Infection	with	Candida	species	was	the	most	common	invasive	fungal	
infection	among	the	TRANSNET	solid	organ	transplant	population.14 
The	present	report	included	surveillance	of	>15%	of	organ	transplants	
occurring	in	the	US	during	the	study	period,	and	is	among	the	largest	
prospective	investigations	reporting	the	epidemiology	and	outcomes	
of	IC	in	solid	OTRs.	The	results	document	the	importance	of	IC	for	this	
growing	patient	population.	A	common	theme	includes	identification	
of	a	high	prevalence	of	comorbidities	in	this	IC	population,	underscor-
ing	the	complexity	of	the	patients	with	IC.	Almost	50%	of	OTRs	had	
renal	 insufficiency,	 one-	fourth	 had	hepatic	dysfunction,	 nearly	 50%	
had	diabetes,	and	30%	had	malnutrition.	Nearly	40%	experienced	epi-
sodes	of	rejection,	which	may	have	contributed	to	the	prevalence	of	
organ	dysfunction	either	 caused	by	 rejection	or	 anti-	rejection	 ther-
apy.	Furthermore,	a	large	percentage	of	patients	had	received	antifun-
gal	prophylaxis	prior	to	development	of	IC.
Against	 this	 backdrop,	 we	 found	 that,	 similar	 to	 other	 epidemio-
logic	 studies	 of	 IC,	C. albicans	 remained	 the	most	 frequent	 pathogen.	
However,	 >10%	 of	 cases	 included	 infection	with	 2	 or	 more	 Candida 
species.	 The	 frequency	 in	 the	 present	 study	 is	 more	 than	 twice	 that	
previously	 reported.21,25–28	 Similar	 to	 prior	 reports,	 this	 epidemiologic	
feature	did	not	impact	outcome	in	this	cohort.	Over	the	last	2	decades,	
the	proportion	of	non-	albicans Candida	species	causing	IC	has	steadily	
increased.9,26,29–33	The	second	most	common	pathogen	 in	the	present	
study	was	C. glabrata.34–36	The	relevance	of	this	increase	in	non-	albicans 
infections	relates	to	potential	for	reduced	treatment	efficacy	with	certain	
antifungals	owing	 to	differences	 in	 susceptibility,	 in	particular,	 the	 re-
duced	susceptibility	of	C. glabrata	and	C. parapsilosis	to	triazole	and	echi-
nocandin	 antifungal	 drugs	 respectively.37–40	 Antifungal	 susceptibility	
testing	of	available	isolates	demonstrated	elevated	minimum	inhibitory	
concentrations	for	these	species	and	drug	combinations.40	Interestingly,	
outcome	for	patients	infected	with	non-	albicans	species	in	this	transplant	
cohort	was	worse	than	for	those	with	disease	caused	by	C. albicans.
It	is	notable	that	we	found	prophylactic	use	of	drugs	from	the	tri-
azole	and	echinocandin	classes	was	common	for	C. glabrata	and	C. para-
psilosis	infections	and	was	statistically	associated	with	poorer	outcome	
for	these	2	species.	The	apparent	superiority	of	the	echinocandin	class	
for	treatment	of	IC,	including	infection	caused	by	C. glabrata,	has	been	
observed	 in	 recent	 analysis.41	 Reduced	 efficacy	 for	 this	 class	 against	
less	susceptible	species,	such	as	C. parapsilosis,	has	not	been	evident	in	
clinical	trials.38,42,43	It	is	possible	that	the	advanced	degree	of	immuno-
suppression	in	this	cohort,	as	suggested	by	the	high	rate	of	both	multi-	
organ	failure	and	allograft	rejection,	 raised	the	therapeutic	hurdle	for	
this	pathogen,	which	is	traditionally	considered	among	the	least	virulent.	
Indeed,	 the	mortality	 rate	 in	 the	 transplant	 population	 infected	with	
C. parapsilosis	 was	 unusually	 high	 compared	 to	 previous	 reports.44,45 
However,	the	relatively	small	number	of	patients	with	C. parapsilosis in 
this	series	precludes	drawing	firm	therapeutic	conclusions.
Another	unique	observation	is	the	relatively	young	age	of	patients	
with	C. glabrata	infections	(<50	years).	Other	large	surveillance	studies	
have	reported	increased	C. glabrata	risk	beyond	the	fifth	decade.20,46,47 
This	finding	may	be	in	part	a	result	of	a	relatively	low	percentage	of	
transplant	 recipients	 above	 the	 fifth	 decade	 in	 this	 cohort	 (50.2%	
age	>50	at	time	of	transplant).	Two	additional	unique	C. glabrata	risk	
factors	of	note	 in	 the	current	 investigation	 include	 the	 relevance	of	
female	gender	and	black	race.	A	similar	race	observation	has	been	de-
scribed	for	cryptococcal	infections	in	the	setting	of	organ	transplanta-
tion.48	However,	the	mechanistic	basis	for	this	epidemiologic	finding	
remains	unclear.	We	also	observed	a	correlation	between	the	use	of	
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MPS	and	non-	albicans Candida	infections,	especially	those	caused	by	
C. glabrata.	We	hypothesize	that	the	use	of	this	higher	potency	corti-
costeroid	 is	a	marker	of	organ	rejection	therapy	reflecting	enhanced	
immunosuppression.	This	observation	is	congruent	with	prior	studies	
that	link	high	mortality	and	C. tropicalis	infection	among	patients	with	
hematologic	malignancies.49–51	We	did	not	identify	unique	transplant	
variables	to	explain	this	observation.
Candidemia	was	the	commonest	microbiologic	manifestation	of	IC	
in	this	study.	The	second	most	common	site	was	intra-	abdominal,	and	
not	surprisingly,	the	majority	of	the	cases	occurred	in	abdominal	cavity	
allografts.52–54	Advanced	disease,	 as	marked	by	categorization	as	dis-
seminated	or	organ	disease	other	than	abdominal	was	observed	in	>10%	
of	patients.	This	rate	of	multi-	organ	involvement	is	comparable	with	re-
ports	of	IC	in	the	non-	transplant	population.7,12,52,53	The	impact	of	the	
pulmonary	infection	site	on	outcome	is	intriguing,	but	the	relevance	un-
clear.	We	speculate	this	could	be	an	indication	of	dissemination	or	sim-
ply	a	high	burden	of	Candida,	as	suggested	in	prior	colonization	studies.
Examination	 of	 antifungal	 choice	 for	 prophylaxis	 and	 therapy	 in	
the	 current	 population	 revealed	 a	 use	 pattern	 consistent	with	 prior	
surveys.12,21,55,56	 Prophylaxis	 was	 dominated	 by	 the	 triazole	 class,	
predominantly	fluconazole.	Definitive	treatment	represented	a	mixed	
approach,	and	included	a	high	percentage	of	echinocandins	and	com-
paratively	little	use	of	polyenes,	probably	owing	to	the	differential	risk	
for	nephrotoxicity.	Triazole	prophylaxis	 in	this	cohort	was	successful	
in	 the	 prevention	 of	 IC	 by	 C. albicans,	 as	 previously	 reported.56–59 
However,	the	rate	of	breakthrough	IC	cases	in	this	cohort	was	striking.	
Analyses	demonstrated	 that	many	emergent	 infections	were	caused	
by	species	with	higher	minimum	inhibitory	concentrations	to	antifun-
gal	compounds.42	In	the	setting	of	triazole	prophylaxis,	infection	with	
TABLE  3 Multivariate	analysis	of	risk	factors	for	mortality	in	
OTRs	with	invasive	candidiasis
Variable
Odds 
ratio Lower Upper P- value
Candida	species	subgroup
All	species
Liver	transplant 1.63 0.96 2.76 .071
Renal	insufficiency 2.31 1.46 3.66 <.001
Hepatic	insufficiency 1.68 0.97 2.91 .066
CHF 3.54 1.61 7.81 .002
Pulmonary	site 2.88 1.35 6.16 .006
Prednisone 0.39 0.25 0.63 <.001
Amphotericin	B 1.99 1.24 3.2 .004
Early	disease 0.51 0.3 0.84 .009
C. albicans
Heart	transplant 0.13 0.03 0.55 .006
Renal	insufficiency 3.77 1.82 7.8 <.001
CHF 3.49 1.2 10.11 .022
Pulmonary	site 2.88 0.86 9.66 .088
Disseminated	site 8.66 1.74 43.01 .008
Prednisone 0.37 0.17 0.8 .012
Methyprednisolone 2.61 0.98 6.93 .054
Amphotericin	B 2.85 1.31 6.22 .009
Echinocandin 3.25 1.4 7.58 .006
Early	disease 0.36 0.15 0.85 .021
C. glabrata
Age 1.05 1.02 1.09 .005
Pancreas	transplant 9.84 1.46 66.26 .019
CHF 25.06 2.71 232.13 .005
Pulmonary	site 5.17 0.68 39.49 .113
Prednisone 0.45 0.18 1.15 .094
Echinocandin 0.4 0.17 0.97 .042
Non-	albicans Candida
Heart 3.86 1.14 13.05 .03
Hepatic	insufficiency 3.25 1.6 6.58 .001
CHF 9.02 1.67 48.57 .011
Pulmonary	site 5.01 1.76 14.28 .003
Prednisone 0.48 0.25 0.93 .029
Early	disease 0.54 0.27 1.09 .084
Transplant	organ	subgroups
Kidney
Hepatic	insufficiency 17.28 4.42 67.53 <.001
CHF 6.29 1.89 20.93 .003
Renal	insufficiency 3.63 1.39 9.44 .008
Prednisone 0.2 0.07 0.57 .003
Amphotericin 5.47 1.89 15.86 .002
Echinocandin 5.91 0.74 47.14 .093
Variable
Odds 
ratio Lower Upper P- value
Liver
Renal	insufficiency 3.12 1.54 6.32 .002
CMV 13.96 3.2 60.88 <.001
COPD 0.24 0.07 0.84 .026
Disseminated	site 4.3 0.92 20.06 .063
Prednisone 0.27 0.13 0.6 .001
Methyprednisolone 0.28 0.09 0.89 .032
Early	disease 0.39 0.18 0.86 .02
Candidemia	subgroup
Renal	insufficiency 2.24 1.39 3.61 <.001
CHF 3.11 1.38 7.02 .006
Prednisone 0.41 0.25 0.68 <.001
Amphotericin 2.63 1.59 4.37 <.001
Echinocandin 2.01 1.22 3.3 .006
Early	disease 0.46 0.27 0.8 .006
OTR,	 organ	 transplant	 recipient;	 CHF,	 congestive	 heart	 failure;	 CMV,	
	cytomegalovirus;	COPD,	chronic	obstructive	pulmonary	disease.
TABLE  3  (Continued)
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TABLE  4 Characteristics	of	OTRs	with	invasive	candidiasis	based	upon	transplant	organ
Variable Heart Lung Pancreas Kidney Liver Kidney- pancreas
Demographics
Age,	mean±SD 52.8±19.3 48.2±15.7 44.5±7.5 48.1±12.9 46.9±17.1 42.6±9.1
Male 35/48	(72.9) 22/54	(40.7) 19/37	(51.4) 112/222	(50.5) 164/259	(63.3) 30/58	(51.7)
Female 13/48	(27.1) 32/54	(59.3) 18/37	(48.6) 110/222	(49.5) 95/259	(36.7) 28/58	(48.3)
Race
Caucasian 39	(83.0) 43	(78.2) 37	(97.4) 167	(74.6) 204	(78.8) 48	(82.8)
Black 3	(6.4) 7	(12.7) 0	(0.0) 43	(19.2) 23	(8.9) 7	(12.1)
Other 5	(10.6) 5	(9.1) 1	(2.6) 14	(6.2) 32	(12.4) 3	(5.2)
Comorbidities
Neutropenia 1/48	(2.1) 1/55	(1.8) 2/38	(5.3) 7/224	(3.1) 12/261	(4.6) 2/58	(3.4)
Fever 20/48	(41.7) 19/55	(34.5) 26/38	(68.4) 115/224	(51.3) 148/261	(56.7) 34/58	(58.6)
Organ	rejection 25/48	(52.1) 22/55	(40.0) 12/37	(32.4) 87/224	(38.8) 88/260	(33.8) 24/58	(41.4)
CMV 4/48	(8.3) 4/55	(7.3) 2/38	(5.3) 12/224	(5.4) 20/261	(7.7) 3/58	(5.2)
Renal	insufficiency 33/48	(68.8) 23/55	(41.8) 8/38	(21.1) 106/224	(47.3) 116/261	(44.4) 22/58	(37.9)
Hepatic	insufficiency 6/48	(12.5) 2/55	(3.6) 1/38	(2.6) 29/224	(12.9) 111/261	(42.5) 6/58	(10.3)
Malnutrition 4/48	(8.3) 10/55	(18.2) 6/38	(15.8) 67/224	(29.9) 95/261	(36.4) 19/58	(32.8)
Diabetes 28/48	(58.3) 18/55	(32.7) 12/38	(31.6) 108/224	(48.2) 130/261	(49.8) 26/58	(44.8)
COPD 3/48	(6.2) 13/55	(23.6) 0/38	(0.0) 16/224	(7.1) 29/261	(11.1) 3/58	(5.2)
CHF 9/48	(18.8) 3/55	(5.5) 2/38	(5.3) 25/224	(11.2) 12/261	(4.6) 5/58	(8.6)
Autoimmune 3/48	(6.2) 6/55	(10.9) 0/38	(0.0) 19/224	(8.5) 15/261	(5.7) 2/58	(3.4)
Pancreatitis 2/48	(4.2) 0/55	(0.0) 2/38	(5.3) 30/224	(13.4) 11/261	(4.2) 11/58	(19.0)
HIV/AIDS 0/48	(0.0) 0/55	(0.0) 0/38	(0.0) 2/224	(0.9) 0/261	(0.0) 0/58	(0.0)
Prednisone 31/48	(64.6) 45/55	(81.8) 26/38	(68.4) 178/224	(79.5) 180/261	(69.0) 43/58	(74.1)
MPS 16/48	(33.3) 10/55	(18.2) 6/38	(15.8) 33/224	(14.7) 42/261	(16.1) 8/58	(13.8)
Candida	species
C. albicans 25	(53.2) 30	(54.5) 18	(47.4) 95	(42.4) 124	(47.9) 27	(46.6)
C. glabrata 9	(19.1) 9	(16.4) 13	(34.2) 62	(27.7) 57	(22.0) 18	(31.0)
C. krusei 2	(4.3) 0	(0.0) 1	(2.6) 6	(2.7) 9	(3.5) 1	(1.7)
C. parapsilosis 4	(8.5) 6	(10.9) 3	(7.9) 22	(9.8) 15	(5.8) 3	(5.2)
C. tropicalis 1	(2.1) 6	(10.9) 0	(0.0) 7	(3.1) 10	(3.9) 1	(1.7)
C. lusitaniae 1	(2.1) 0	(0.0) 0	(0.0) 3	(1.3) 1	(0.4) 0	(0.0)
Multiple 3	(6.4) 3	(5.5) 3	(7.9) 21	(9.4) 38	(14.7) 6	(10.3)
Other 1	(2.1) 0	(0.0) 0	(0.0) 3	(1.3) 4	(1.5) 1	(1.7)
Unspecified 1	(2.1) 1	(1.8) 0	(0.0) 5	(2.2) 1	(0.4) 1	(1.7)
Infection	site
Bloodstream 31/48	(64.6) 29/55	(52.7) 12/38	(31.6) 99/224	(44.2) 107/261	(41.0) 15/58	(25.9)
Abdominal 0/48	(0.0) 0/55	(00.0) 10/38	(26.3) 26/224	(11.6) 54/261	(20.7) 11/58	(19.0)
Pulmonary 4/48	(8.3) 17/55	(30.9) 1/38	(2.6) 3/224	(1.3) 9/261	(3.4) 1/58	(1.7)
Disseminated 3/48	(6.2) 0/55	(0.0) 1/38	(2.6) 9/224	(4.0) 10/261	(3.8) 2/58	(3.4)
CNS 0/48	(0.0) 0/55	(0.0) 0/38	(0.0) 3/224	(1.3) 1/261	(0.4) 0/58	(0.0)
Antifungal	therapy1
Triazole 31/48	(64.6) 38/55	(69.1) 28/38	(73.7) 158/224	(70.5) 158/261	(60.5) 39/58	(67.2)
Amphotericin 14/48	(29.2) 15/55	(27.3) 9/38	(23.7) 59/224	(26.3) 82/261	(31.4) 17/58	(29.3)
Echinocandin 13/48	(27.1) 10/55	(18.2) 14/38	(36.8) 85/224	(37.9) 102/261	(39.1) 24/58	(41.4)
(Continues)
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C. glabrata	was	common.	This	observation	is	congruent	with	previously	
reported	prophylaxis	studies.18	Interestingly,	we	also	found	an	associ-
ation	between	 echinocandin	 prophylaxis	 and	 infection	with	C. para-
psilosis	(6/52,	11.5%),	and	this	finding	is	consistent	with	the	reduced	
efficacy	described	in	the	setting	of	definitive	therapy	described	above.
A	number	of	comorbidities	were	strongly	related	to	poor	outcomes.	
Neutropenia,	 heart	 failure,	 and	 renal	 and	 hepatic	 dysfunction	 each	
conferred	a	negative	impact	on	outcome.	Interestingly,	we	found	a	dis-
parate	impact	for	2	corticosteroid	formulations,	prednisone	and	MPS.	
As	noted	above,	we	theorize	that	use	of	MPS	is	a	marker	of	rejection	
and	this	likely	translates	into	a	risk	for	poor	outcome.	Conversely,	use	
of	prednisone	may	suggest	stable	allograft	function	and	may	explain	
the	 observed	 “protective”	 nature	 of	 this	 therapy.	 Early	 disease	was	
also	predictive	of	a	favorable	outcome.	We	theorize	that	this	improve-
ment	may	be	a	result	of	earlier	diagnosis	linked	to	enhanced	vigilance	
in	the	early	post-	transplant	period.
The	 results	 of	 this	 survey	 both	 confirm	 and	 extend	 our	 under-
standing	of	the	features	of	IC	in	solid	OTRs.	We	identified	a	hierarchy	
of	risk	for	disease	and	outcome	based	on	transplant	type,	underlying	
disease,	and	comorbid	conditions.	We	did	not	identify	directly	modi-
fiable	factors,	other	than	an	emphasis	on	the	importance	of	drug	se-
lection	for	certain	Candida	species,	which	is	intuitive	based	upon	fairly	
predictable	antifungal	drug	susceptibility.	Current	evidence	suggests	
that	echinocandins	are	the	optimal	empiric	antifungal	drug	choice	for	
IC.43	In	the	current	study,	this	benefit	is	less	clear	for	infection	caused	
by C. parapsilosis,	but	numbers	are	small.	The	absence	of	other	readily	
identifiable	factors	under	the	direct	control	of	clinicians	underscores	
the	 importance	of	 a	high	 index	of	 suspicion	 in	 this	 complex	patient	
population.	 In	particular,	 the	presence	of	organ	dysfunction	and	 re-
jection	 should	 prompt	 surveillance	 for	 this	 infectious	 complication.	
Furthermore,	these	observations	highlight	the	need	for	improved	fun-
gal	diagnostics	and	more	effective	antifungal	compounds.
The	 TRANSNET	 database	 is	 comprehensive,	 but	 it	 has	 several	
limitations.	 Baseline	 and	 longitudinal	 laboratory	 data	 were	 minimal	
and	 specific	 information	 about	 drug	 exposure	was	 incomplete.	 For	
example,	information	regarding	antifungal,	antiviral,	and	antibacterial	
prophylaxis	was	limited,	as	were	data	pertaining	to	vascular	catheter	
management,	 immunosuppressive	 regimens,	 and	 institution-	specific	
practices	and	protocols.	It	is	possible	that	information	regarding	cath-
eters	may	 have	 shed	 light	 on	 the	 relatively	 high	mortality	 linked	 to	
C. parapsilosis	infection.	Moreover,	the	dataset	does	not	include	data	
on	 disease	 severity	 and	 transplant	 incompatibility	 characteristics.	
These	 important	 covariates	 should	 be	 explored	more	 fully	 in	 future	
studies.	In	addition,	the	period	of	data	collection	ended	in	2006,	thus	
practice	changes	may	have	occurred	that	 limit	extrapolation	of	find-
ings.	For	example,	echinocandins	have	emerged	as	the	preferred	ther-
apy	for	treatment	of	 IC	over	AmB	and	triazoles.	 Immunosuppressive	
and	antifungal	prophylaxis	regimens	also	continue	to	evolve.	Finally,	
this	analysis	 is	based	on	all-	cause	mortality,	as	attribution	to	IC	as	a	
contributing	cause	 to	mortality	 is	difficult,	 and	generally	 reflects	 in-
vestigator	opinion.	Despite	these	limitations,	this	analysis	from	a	large	
and	comprehensive	database	provides	important	insights	into	factors	
that	are	associated	with	mortality	among	OTRs	who	develop	IC,	and	
these	data	may	be	useful	in	developing	strategies	for	prevention	and	
treatment	of	this	important	post-	transplantation	complication.
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Supplemental TABLE S1.  Characteristics of OTR patients with invasive candidiasis based upon transplant organ 
Variable Heart Lung Pancreas Kidney Liver Kidney-Pancreas 
Demographics 
Age mean ± SD 52.8 ± 19.3 48.2 ± 15.7 44.5 ± 7.5 48.1 ± 12.9 46.9 ± 17.1 42.6 ± 9.1 
Male 35/48 (72.9) 22/54 (40.7) 19/37 (51.4) 112/222 (50.5) 164/259 (63.3) 30/58 (51.7) 
Female 13/48 (27.1) 32/54 (59.3) 18/37 (48.6) 110/222 (49.5) 95/259 (36.7) 28/58 (48.3) 
Race 
  Caucasian  39 (83.0) 43 (78.2) 37 (97.4) 167 (74.6) 204 (78.8) 48 (82.8) 
  Black 3 (6.4) 7 (12.7) 0 (0.0) 43 (19.2) 23 (8.9) 7 (12.1) 
  Other 5 (10.6) 5 (9.1) 1 (2.6) 14 (6.2) 32 (12.4) 3 (5.2) 
Comorbidities 
Neutropenia 1/48 (2.1)   1/55 (1.8) 2/38 (5.3) 7/224 (3.1) 12/261 (4.6) 2/58 (3.4) 
Fever 20/48 (41.7) 19/55 (34.5) 26/38 (68.4) 115/224 (51.3) 148/261 (56.7) 34/58 (58.6) 
Organ Rejection 25/48 (52.1) 22/55 (40.0) 12/37 (32.4) 87/224 (38.8) 88/260 (33.8) 24/58 (41.4) 
CMV 4/48 (8.3) 4/55 (7.3) 2/38 (5.3) 12/224 (5.4) 20/261 (7.7) 3/58 (5.2) 
Renal insufficiency 33/48 (68.8) 23/55 (41.8) 8/38 (21.1) 106/224 (47.3) 116/261 (44.4) 22/58 (37.9) 
Hepatic 
insufficiency 
6/48 (12.5) 2/55 (3.6) 1/38 (2.6) 29/224 (12.9) 111/261 (42.5) 6/58 (10.3) 
Malnutrition 4/48 (8.3) 10/55 (18.2) 6/38 (15.8) 67/224 (29.9) 95/261 (36.4) 19/58 (32.8) 
Diabetes 28/48 (58.3) 18/55 (32.7) 12/38 (31.6) 108/224 (48.2) 130/261 (49.8) 26/58 (44.8) 
COPD 3/48 (6.2) 13/55 (23.6) 0/38 (0.0) 16/224 (7.1) 29/261 (11.1) 3/58 (5.2) 
CHF 9/48 (18.8) 3/55 (5.5) 2/38 (5.3) 25/224 (11.2) 12/261 (4.6) 5/58 (8.6) 
Autoimmune 3/48 (6.2) 6/55 (10.9) 0/38 (0.0) 19/224 (8.5) 15/261 (5.7) 2/58 (3.4) 
Pancreatitis 2/48 (4.2) 0/55 (0.0) 2/38 (5.3) 30/224 (13.4) 11/261 (4.2) 11/58 (19.0) 
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Variable Heart Lung Pancreas Kidney Liver Kidney-Pancreas 
HIV/AIDS 0/48 (0.0) 0/55 (0.0) 0/38 (0.0) 2/224 (0.9) 0/261 (0.0) 0/58 (0.0) 
Prednisone 31/48 (64.6) 45/55 (81.8) 26/38 (68.4) 178/224 (79.5) 180/261 (69.0) 43/58 (74.1) 
Methylpred 16/48 (33.3) 10/55 (18.2) 6/38 (15.8) 33/224 (14.7) 42/261 (16.1) 8/58 (13.8) 
Candida species 
  C.  albicans 25 (53.2) 30 (54.5) 18 (47.4) 95 (42.4) 124 (47.9) 27 (46.6) 
  C.  glabrata 9 (19.1) 9 (16.4) 13 (34.2) 62 (27.7) 57 (22.0) 18 (31.0) 
  C.  krusei 2 (4.3) 0 (0.0) 1 (2.6) 6 (2.7) 9 (3.5) 1 (1.7) 
  C.  parapsilosis 4 (8.5) 6 (10.9) 3 (7.9) 22 (9.8) 15 (5.8) 3 (5.2) 
  C.  tropicalis 1 (2.1) 6 (10.9) 0 (0.0) 7 (3.1) 10 (3.9) 1 (1.7) 
  C.  lusitaniae 1 (2.1) 0 (0.0) 0 (0.0) 3 (1.3) 1 (0.4) 0 (0.0) 
  Multiple 3 (6.4) 3 (5.5) 3 (7.9) 21 (9.4) 38 (14.7) 6 (10.3) 
  Other 1 (2.1) 0 (0.0) 0 (0.0) 3 (1.3) 4 (1.5) 1 (1.7) 
  unspecified 1 (2.1) 1 (1.8) 0 (0.0) 5 (2.2) 1 (0.4) 1 (1.7) 
Infection site 
Bloodstream 31/48 (64.6) 29/55 (52.7) 12/38 (31.6) 99/224 (44.2) 107/261 (41.0) 15/58 (25.9) 
Abdominal 0/48 (0.0) 0/55 (00.0) 10/38 (26.3) 26/224 (11.6) 54/261 (20.7) 11/58 (19.0) 
Pulmonary 4/48 (8.3) 17/55 (30.9) 1/38 (2.6) 3/224 (1.3) 9/261 (3.4) 1/58 (1.7) 
Disseminated 3/48 (6.2) 0/55 (0.0) 1/38 (2.6) 9/224 (4.0) 10/261 (3.8) 2/58 (3.4) 
CNS 0/48 (0.0) 0/55 (0.0) 0/38 (0.0) 3/224 (1.3) 1/261 (0.4) 0/58 (0.0) 
Antifungal therapy* 
Triazole 31/48 (64.6) 38/55 (69.1) 28/38 (73.7) 158/224 (70.5) 158/261 (60.5) 39/58 (67.2) 
Amphotericin 14/48 (29.2) 15/55 (27.3) 9/38 (23.7) 59/224 (26.3) 82/261 (31.4) 17/58 (29.3) 
Echinocandin 13/48 (27.1) 10/55 (18.2) 14/38 (36.8) 85/224 (37.9) 102/261 (39.1) 24/58 (41.4) 
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Variable Heart Lung Pancreas Kidney Liver Kidney-Pancreas 
Antifungal prophylaxis 
Triazole 19/48 (39.6) 24/55 (43.6) 11/38 (28.9) 58/224 (25.9) 70/261 (26.8) 26/58 (44.8) 
Amphotericin 2/48 (4.2) 12/55 (21.8) 0/38 (0.0) 2/224 (0.9) 33/261 (12.6) 1/58 (1.7) 
Echinocandin 1/48 (2.1) 3/55 (5.5) 0/38 (0.0) 7/224 (3.1) 14/261 (5.4) 3/58 (5.2) 
*Includes sequential or combination therapy. 
OTR, organ transplant recipients; SD, standard deviation; CMV, cytomegalovirus; COPD, chronic obstructive pulmonary disease; CHF, congestive 
heart failure; CMV, cytomegalovirus; HIV/AIDS, human immunodeficiency virus/acquired immunodeficiency syndrome; Methylpred, 
methylprednisolone; CNS, central nervous system. 
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Supplemental Data: 
 
Co-Morbidity Definitions: 
Diabetes  
Any patient requiring oral hypoglycemic agents or insulin to maintain control of blood 
sugar will be defined as having diabetes mellitus. Among patients receiving total 
parenteral nutrition (TPN) who develop hyperglycemia only during periods in which they 
are receiving TPN should not be considered in this category. Patients who develop post-
transplantation diabetes due to glucocorticosteroids or other factors and who require oral 
agents or insulin for blood sugar control should be included.  
 
Malnutrition  
A serum albumin of ≤ 2 g/dL will be sufficient to make a diagnosis of malnutrition. For 
patient with serum albumin between 2.1 and 2.5 g/dL, malnutrition will be considered if 
the patient is ≤ 5% below ideal body weight.  
Chronic Renal Insufficiency  
Renal insufficiency will be defined as patients with either a chronically elevated serum 
creatinine of ≥3.0 or a creatinine clearance ≤ 30 cc/min.  
Hepatic Insufficiency  
Hepatic insufficiency will be defined in clinical terms as the presence of ascites without 
other cause, typical stigmata of chronic liver disease including jaundice, spider 
angiomata, peripheral wasting, etc. Laboratory evidence of hepatic insufficiency may 
include any of the following: elevated serum ammonia, direct hyperbilirubinemia, and 
evidence of decreased protein synthetic function as evidenced by hypoalbuminemia or 
prolonged prothrombin time (increased INR).  
 
Pancreatitis  
Acute or chronic pancreatitis will be defined by abnormal lipase or amylase assays, or 
radiologic evidence revealing pancreatic inflammation or calcification.  
 
 
 
Definition of Proven Invasive Candidiasis: 
Histopathologic, cytopathologic, or direct microscopic examination of a specimen obtained by 
needle aspiration or biopsy from a normally sterile site (other than mucous membranes) 
showing yeast cells—for example, Candida species showing pseudohyphae or true hyphae. 
or 
Recovery of a yeast by culture of a sample obtained by a sterile procedure (including a freshly 
placed [<24 h ago] drain) from a normally sterile site showing a clinical or radiological 
abnormality consistent with an infectious disease process. 
or 
Blood culture that yields Candida species. 
 
Definition Probable Invasive Candidiasis: Requires the presence of a host factor, a clinical 
criterion, and a mycological criterion. Cases that meet the criteria for a host factor and a clinical 
criterion but for which mycological criteria are absent are considered possible invasive fungal 
disease. 
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Host factors 
- Recent history of neutropenia (<0.5 × 109 neutrophils/L [<500 neutrophils/mm3] for >10 days) 
temporally related to the onset of fungal disease 
- Receipt of an allogeneic stem cell transplant 
- Prolonged use of corticosteroids (excluding among patients with allergic bronchopulmonary 
aspergillosis) at a mean minimum dose of 0.3 mg/kg/day of prednisone equivalent for >3 weeks 
-Treatment with other recognized T cell immunosuppressants, such as cyclosporine, tumor 
necrosis factor-α blockers, specific monoclonal antibodies (such as alemtuzumab), or 
nucleoside analogues during the past 90 days 
- Inherited severe immunodeficiency (such as chronic granulomatous disease or severe 
combined immunodeficiency) 
 
Clinical criteria 
Acute localized pain (including pain radiating to the eye) 
Central nervous system infection 
1 of the following 2 signs: 
Focal lesions on imaging 
Meningeal enhancement on magnetic resonance imaging or computed tomography 
 
Disseminated candidiasis 
At least 1 of the following 2 entities after an episode of candidemia within the previous 2 weeks: 
Small, target-like abscesses (bull's-eye lesions) in liver or spleen or progressive retinal exudates 
on ophthalmologic examination 
 
Mycological criteria 
Direct test (cytology, direct microscopy, or culture) 
 
